Invex Therapeutics Ltd (ASX: IXC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Invex Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $7.34 million
P/E Ratio 56.25
Dividend Yield 0.00%
Shares Outstanding 86.40 million
Earnings per share -0.018
Dividend per share 0.19
Year To Date Return -29.17%
Earnings Yield 1.78%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Invex Therapeutics Ltd (ASX: IXC)
    Latest News

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Share Gainers

    This ASX healthcare company just got FDA approval, and its share price is soaring 18%

    Invex Therapeutics is exciting the market today after announcing some big news.

    Read more »

    IXC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Invex Therapeutics Ltd

    Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. It focuses in understanding and defining the mechanisms that regulate pressure in the brain and aims to repurpose and reformulate an already approved drug, Exenatide. The company was founded by Jason Loveridge and Alexandra J. Sinclair on March 8, 2019 and is headquartered in Subiaco, Australia.

    IXC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Nov 2026 $0.09 $0.00 0.00% 3,035 $0.09 $0.09 $0.09
    11 Nov 2026 $0.09 $0.00 0.00% 4,223 $0.09 $0.09 $0.09
    03 Nov 2026 $0.09 $-0.01 -10.00% 24,638 $0.09 $0.09 $0.09
    27 Oct 2026 $0.10 $-0.02 -16.67% 86,747 $0.10 $0.10 $0.10
    26 Oct 2026 $0.12 $0.02 19.05% 475,676 $0.11 $0.12 $0.11

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Simon Llewellyn Owen Non-Executive Director Nov 2025
    Mr Owen has over 35 years of experience as a corporate and commercial lawyer and corporate advisor with a particular focus on developing businesses, innovation and intellectual property and capital markets. He has acted as a chairman and director, both executive and non-executive, for several listed and unlisted public companies.
    Mr David Colin Wheeler Non-Executive ChairmanNon-Executive Director Nov 2023
    Mr Wheeler has more than 30 years of Senior Executive Management, Directorships, and Corporate Advisory experience. He is a foundation Director and Partner of Pathways Corporate, a boutique Corporate Advisory firm that undertakes assignments on behalf of family offices, private clients, and ASX listed companies. Mr Wheeler is a Fellow of the Australian Institute of Company Directors (FAICD).
    Professor Warren John Harding Non-Executive Director Nov 2025
    Prof Harding is an experienced company director with more than 30 years of leadership experience across global healthcare, biotech and medtech industries. He was Managing Partner in global strategy/ consulting companies Accenture, Deloitte and PWC including Senior Adviser to McKinsey & Co and has experience in corporate governance, strategic transformation and growth. He has been involved in various mergers/acquisitions at a global and national level.
    Mr Timothy (Tim) Ryan Slate Company Secretary Nov 2025
    -
    Timothy (Tim) Ryan Slate Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Tattarang 8,846,154 11.77%
    Peterson 5,600,000 7.45%
    Tisia Nominees Pty Ltd <Henderson Family A/C> 3,725,000 4.96%
    Mr Jason Loveridge 3,374,462 4.49%
    Mr David Jerimiah Mcauliffe 2,850,001 3.79%
    JK Nominees Pty Ltd <The JK Fund A/C> 2,750,000 3.66%
    Dr Paul Francis Worth 2,500,000 3.33%
    Celtic Finance Corp Pty Ltd 2,390,000 3.18%
    Mrs Kathryn Salkild 2,293,000 3.05%
    Porjed Pty Ltd <Deporj A/C> 2,239,817 2.98%
    Bannaby Investments Pty Limited <Bannaby Super Fund A/C> 1,625,000 2.16%
    Warragoon Investments Pty Ltd 1,500,000 2.00%
    Rock The Polo Pty Ltd <Rock The Polo A/C> 1,400,000 1.86%
    Anthony Grist 1,338,518 1.78%
    Hammerhead Holdings Pty Ltd <HHH S/F A/C> 1,000,000 1.33%
    Mr Andrew Clayton <The King Carey A/C> 1,000,000 1.33%
    Zerrin Investments Pty Ltd 1,000,000 1.33%
    Chelsea Investments (WA) Pty Ltd 950,000 1.26%
    Okanagan Trading Pty Ltd 900,000 1.20%
    Mr Anthony De Nicola & Mrs Tanya Louise De Nicola <De Nicola Family S/F A/C> 825,000 1.10%

    Profile

    since

    Note